NeurologyLive®

As the second half of 2025 begins, the neurology field is bracing for a series of pivotal clinical trial readouts. 🧪 These results could shift diagnostic paradigms, guide treatment decisions, and expand the reach of innovative therapies—from neuromodulation devices to cell-based…

📢 In case you missed this: John Sims, MD, of Eli Lilly, joined us to walk through the Trailblazer-ALZ-6 trial and what the latest FDA label update for donanemab means for neurologists. 🧠 Key episode themes: • Stratified genotype risk + personalized treatment conversations •…

Weekly complement C5 inhibition shows promise in gMG: AstraZeneca’s gefurulimab succeeds across all key outcomes in the PREVAIL phase 3 trial. Regulatory talks ahead. 🧬 #MyastheniaGravis #NeuroNews Details: hubs.li/Q03yZX8_0

The 2025 Alzheimer's Association International Conference (AAIC) kicks off this weekend! We'll be live in Toronto covering the latest research and data from the conference, with clinical perspectives 🧠👩‍🔬 to match. hubs.li/Q03yZYm40

Our latest Clinical Trial in Focus covers the AHEAD 3-45 study, an innovative trial testing lecanemab (Leqembi; Eisai) in patients with preclinical Alzheimer disease. Read more about the unique aspects to this large-scale study, which consists of 2 sister trials, known as the…

✈️Off to #AAIC25 in Toronto! Excited to share our new research 🧠🧬 • Tau PET & genetic variants • APOE, HDL, & WMH • Longitudinal tau PET & inflammation • DMN & glucose in aging & T2DM See our full presentation lineup ⬇️ 👋Come talk science with us!

Prepare slides for tomorrow #AAIC25 now! Cheng lab will present 5 talks and 10 posters in coming few days. Exciting to meet colleagues, collaborators, old and new friends to discuss emerging Alzheimer’s research, science and therapeutics to fight Alzheimer’s disease!!! @NIHAging

This month, we're excited to spotlight Dr. Dedrick Jordan, who recently began a new role as Professor and Chair of Neurology at the University of Arizona. Dr. Jordan is known for his pioneering work in optimizing medication dosing for acute neurological illnesses and for…

In episode 2 of our new SLEEP Special Report, panelists Eric Olson, MD, and Anita Shelgikar, MD, examine interim data on high-dose low-sodium oxybate in patients with narcolepsy, discussing safety signals, efficacy trends, and clinical considerations👩‍⚕️🏥 View ep:…

A new nationwide observational Norwegian cohort study published in @GreenJournal identified several preexisting prescription therapies associated with reduced mortality risk over an 8-year period in patients with #ParkinsonDisease. #MovementDisorders View now:…

In a newly published @MayoClinic study, researchers used paired MRI at attack and remission, revealing that a resolution of 1 or more brain T2-lesions could differentiate #MOGAD from #MS with high sensitivity and specificity. Details here: hubs.li/Q03yPDnS0

Excited for #AAIC2025 to kick off this weekend! AAIC always brings great science and the added bonus of being able to connect with friends #teamscience Neuropath folks, let’s keep the annual photo tradition alive 📍Tuesday @ 10:45a by registration Please RT

💡 New Mind Moments🚨: John Sims, MD, from @EliLillyandCo, gives us the inside track on donanemab’s label update, ARIA risk management, and the future of Alzheimer’s care. Key takeaways: • 41% drop in ARIA with modified titration strategy • Why genotype and amyloid burden…

In recent company update, @AstraZeneca has announced positive data from its phase 3 PREVAIL study of gefurulimab, a complement C5 inhibitor administered once-weekly, meeting primary and all secondary end points in patients with generalized #MyastheniaGravis. Read More:…

Navigating insurance hurdles for multiple sclerosis treatments poses significant risks, as seen in a patient's devastating relapse after denied care. Read the latest feature from Dr. William Kilgo, MD, Director of the Neurology Residency Program at the University of South…

We have a new updated dosing label for donanemab, but what does it mean for clinicians? How will it impact the healthcare system? John Sims, MD, trial investigator for TRAILBLAZER-ALZ 6, stopped by to discuss🎙️💬 📲neurologylive.com/view/donanemab…

A potential new era in OSA treatment is on the horizon. 🌙 Apnimed’s investigational therapy AD109 has now shown positive phase 3 data in both the LunAIRo and SynAIRgy trials. The once-daily, oral agent combines aroxybutynin and atomoxetine—offering an alternative to traditional…

Join us online Thursday 9/4 for a unique evening where five incredible authors share their powerful journeys with #migraine and #clusterheadache through the written word. Attendees will be entered into a raffle to win one of FIVE signed books! eventbrite.com/e/migraine-hea…

The 2025 LGS Research Meeting of the Minds exceeded all expectations! Thanks again to everyone who made it possible! 🧠🔬🧬

🎙️ BeeWellWithMS episode! Dr. Agne Straukiene & Dr. Antonio Scalfari unpack Aggressive vs. Highly Active MS using vivid metaphors & key biomarkers. 🎧 Listen on all platforms: beewellwithms.com 📺 Watch: youtu.be/K_O-lYSME3s?si… #MS #Podcast #Neurology

As we mark the 1 year anniversary of the passing of our beloved founder, CEO, friend, and guiding star, June Halper, we continue to feel the profound impact of her loss. Though she is no longer with us, her legacy lives on. cmscfoundation.org/donate/